Bronchopulmonary DysplasiaVPOCHNCT06512935
Ventilator Pressure and Optimization of Compliance and Hemodynamics
A study testing Increase in the PEEP followed by decrease in the PEEP and Decrease in the PEEP followed by increase in the PEEP in people with Bronchopulmonary Dysplasia and Pulmonary Hypertension Due to Lung Diseases and Hypoxia, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. Read more about this study
- Who is it for?
- Ages 7 to 30 days
- Conditions the study is for
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity
- What is being tested?
- Increase in the PEEP followed by decrease in the PEEP and Decrease in the PEEP followed by increase in the PEEP
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2026to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 30 days
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age < 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV.
- Post-natal age > 7 days and less than 1 month (outside golden week protocol)
- Gestational age ≥ 21 weeks and ≤ 34 week
- Infants with written informed consent obtained from legal guardian
Who cannot join
- Blood culture-positive sepsis
- Congenital anomalies affecting respiration
- Cyanotic or ductal-dependent congenital heart disease
- Newborns who are considered too unstable for study enrolment per neonatology attending
- Newborns on pressors or steroids for maintaining cardiac output
- Non-invasive ventilation or newborn with significant BPD (bronchopulmonary dysplasia) with pulmonary hypertension (HTN)
- Open skin wounds or abrasions on the chest wall.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Colm P Travers, MD contact
United States1 site, 1 recruiting
- Recruiting
Univerisity of Alabama
Birmingham, Alabama, 35233
About this study
Official title: Ventilator Pressure and Optimization of Compliance and Hemodynamics: VPOCH Trial
In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants.
Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline to determine compliance, oxygenation, and cardiac hemodynamics at each step using echocardiography (ECHO) and EIT measurements. There will be a 15-minute washout period after changes prior to data collection.
Read the detailed description
In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with EIT to optimize ventilator settings in preterm infants.
Neonatal ventilation is a critical intervention to support breathing for newborns with respiratory distress syndrome (RDS), underdeveloped lungs, and evolving bronchopulmonary dysplasia (BPD). Positive airway pressure helps maintain patency of the airways and improves ventilation and oxygenation by maintaining the functional residual capacity (FRC) and keeping the alveoli patent. Peak inspiratory pressure (PIP) and positive end-expiratory pressure (PEEP) are terms commonly used in mechanical ventilation to describe the pressures applied to the respiratory system during the different phases of the breathing cycle. These parameters are essential in managing and optimizing ventilation for infants with respiratory failure.
This study will include preterm infants with recovering RDS born at age < 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on high-frequency jet ventilation (HFJV). Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and each subsequent PEEP.
Following informed consent, randomization will be performed using sequentially numbered sealed opaque envelopes. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.
This will be a single-center, randomized crossover study. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.
Randomization will occur after a baseline assessment of cardiac hemodynamics and respiratory status at the current set PEEP level. Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease versus decrease followed by increase. Randomization will use opaque sealed envelopes of varying block sizes from 2-4 with a 1:1:1:1 allocation ratio.
Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline and there will be a 15-minute washout period after changes before data collection.
All infants enrolled in the study will have routine monitoring, uniform target saturation ranges of 91-95% with alarm limits set at 88-95%, and standard care for the duration of the study. Pulse oximetry recordings will be downloaded using ixTrend (iexcellence, Wildau, Germany) software to a secure computer system for later data analysis.
Infants will continue standard treatment as recommended by the treating physician and will act as their own controls.
Primary secondary outcomes are described below. Electrical impedance tomography data will be collected in the Syntec machine and safely secured in the university computer system. Pulse oximetry recordings will be downloaded using ixTrend software to a secure computer system for later data analysis.
ECHO results will be stored in the unit ECHO machine and results will be reported by certified cardiologists blinded to the data collected to improve the study design's internal and external validity.
- Conditions
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
- Being tested
- Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
- Keywords
- Respiratory distress syndrome, ventilation mechanics in newborn, cardiac hemodynamics newborn
- Medical subject headings
- Bronchopulmonary Dysplasia, Hypoxia, Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Increase in the PEEP followed by decrease in the PEEPOther
Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
Decrease in the PEEP followed by increase in the PEEPOther
Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
| Study group | Role | What they receive |
|---|---|---|
| cardiac hemodynamics and respiratory status assessment with increasing PEEP | Experimental | Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease in PEEP.
Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT Receives: Other: Increase in the PEEP followed by decrease in the PEEP |
| cardiac hemodynamics and respiratory status assessment with decreasing PEEP | Active comparator | Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - decrease followed by increase in PEEP.
Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT Receives: Other: Decrease in the PEEP followed by increase in the PEEP |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT
Measured: During a 4 hour cross-over period on either intervention
PEEP of best compliance and best oxygenation as per EIT measurements
Measured: During a 4 hour cross-over period on either intervention
Secondary outcomes (7)
Tidal volume variation
Measured: During a 4 hour cross-over period on either intervention
Oxygen saturation index
Measured: During a 4 hour cross-over period on either intervention
End-expiratory lung impedance (EELI), End-inspiratory lung impedance (EILI)
Measured: During a 4 hour cross-over period on either intervention
Transcutaneous carbon dioxide (TcCO2) values in response to varying PEEP levels
Measured: During a 4 hour cross-over period on either intervention
Respiratory Severity Score (RSS)
RSS: mean airway pressure (MAP) x fraction of inspired oxygen (FiO2)
Measured: During a 4 hour cross-over period on either intervention
oxygen saturation (SpO2) values
Measured: During a 4 hour cross-over period on either intervention
% tidal distribution
Measured: During a 4 hour cross-over period on either intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2024
- Study start1 Oct 2026
- Primary completion1 May 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bronchopulmonary DysplasiaStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Single centre, randomized crossover study. This study will include preterm infants with recovering RDS born at age \< 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on HFJV. Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and at each subsequent PEEP.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kulsajan Singh Bhatia, University of Alabama at Birmingham
- Investigators
- Kulsajan S Bhatia, MD, Principal investigator, University of Alabama at BirminghamColm P Travers, MD, Principal investigator, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06512935
- Sponsor's protocol ID
- IRB-300013132
- Other IDs
- UAB
- Acronym
- VPOCH
- Status last verified
- Oct 2026
- First submitted
- 5 Jul 2024
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ventilator Pressure and Optimization of Compliance and Hemodynamics: VPOCH Trial
- ClinicalTrials.gov ID
- NCT06512935
- Acronym / sponsor ID
- VPOCH / IRB-300013132
- Conditions
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
- Keywords
- Respiratory distress syndrome, ventilation mechanics in newborn, cardiac hemodynamics newborn
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- University of Alabama at BirminghamUniversity, hospital or other
- Study start
- 1 Oct 2026 (actual)
- Primary completion
- 1 May 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 22 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants.
Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline to determine compliance, oxygenation, and cardiac hemodynamics at each step using echocardiography (ECHO) and EIT measurements. There will be a 15-minute washout period after changes prior to data collection.
Detailed description
In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with EIT to optimize ventilator settings in preterm infants.
Neonatal ventilation is a critical intervention to support breathing for newborns with respiratory distress syndrome (RDS), underdeveloped lungs, and evolving bronchopulmonary dysplasia (BPD). Positive airway pressure helps maintain patency of the airways and improves ventilation and oxygenation by maintaining the functional residual capacity (FRC) and keeping the alveoli patent. Peak inspiratory pressure (PIP) and positive end-expiratory pressure (PEEP) are terms commonly used in mechanical ventilation to describe the pressures applied to the respiratory system during the different phases of the breathing cycle. These parameters are essential in managing and optimizing ventilation for infants with respiratory failure.
This study will include preterm infants with recovering RDS born at age < 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on high-frequency jet ventilation (HFJV). Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and each subsequent PEEP.
Following informed consent, randomization will be performed using sequentially numbered sealed opaque envelopes. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.
This will be a single-center, randomized crossover study. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.
Randomization will occur after a baseline assessment of cardiac hemodynamics and respiratory status at the current set PEEP level. Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease versus decrease followed by increase. Randomization will use opaque sealed envelopes of varying block sizes from 2-4 with a 1:1:1:1 allocation ratio.
Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline and there will be a 15-minute washout period after changes before data collection.
All infants enrolled in the study will have routine monitoring, uniform target saturation ranges of 91-95% with alarm limits set at 88-95%, and standard care for the duration of the study. Pulse oximetry recordings will be downloaded using ixTrend (iexcellence, Wildau, Germany) software to a secure computer system for later data analysis.
Infants will continue standard treatment as recommended by the treating physician and will act as their own controls.
Primary secondary outcomes are described below. Electrical impedance tomography data will be collected in the Syntec machine and safely secured in the university computer system. Pulse oximetry recordings will be downloaded using ixTrend software to a secure computer system for later data analysis.
ECHO results will be stored in the unit ECHO machine and results will be reported by certified cardiologists blinded to the data collected to improve the study design's internal and external validity.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Single centre, randomized crossover study. This study will include preterm infants with recovering RDS born at age < 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on HFJV. Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and at each subsequent PEEP.
| Arm | Type | Receives |
|---|---|---|
| cardiac hemodynamics and respiratory status assessment with increasing PEEP | Experimental | Other: Increase in the PEEP followed by decrease in the PEEPInfants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease in PEEP. Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT |
| cardiac hemodynamics and respiratory status assessment with decreasing PEEP | Active comparator | Other: Decrease in the PEEP followed by increase in the PEEPInfants will be randomized to the order of changes in PEEP levels during mechanical ventilation - decrease followed by increase in PEEP. Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT |
Who may qualify
- Ages
- 7 to 30 days
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age < 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV.
- Post-natal age > 7 days and less than 1 month (outside golden week protocol)
- Gestational age ≥ 21 weeks and ≤ 34 week
- Infants with written informed consent obtained from legal guardian
Key exclusion criteria (7 listed)
- Blood culture-positive sepsis
- Congenital anomalies affecting respiration
- Cyanotic or ductal-dependent congenital heart disease
- Newborns who are considered too unstable for study enrolment per neonatology attending
- Newborns on pressors or steroids for maintaining cardiac output
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Increase in the PEEP followed by decrease in the PEEPChanges in the ventilator PEEP and its effect on lung and cardiac hemodynamics | Other | cardiac hemodynamics and respiratory status assessment with increasing PEEP |
| Decrease in the PEEP followed by increase in the PEEPChanges in the ventilator PEEP and its effect on lung and cardiac hemodynamics | Other | cardiac hemodynamics and respiratory status assessment with decreasing PEEP |
Primary outcome
Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT
Time frame: During a 4 hour cross-over period on either intervention
PEEP of best compliance and best oxygenation as per EIT measurements
Time frame: During a 4 hour cross-over period on either intervention
7 secondary outcomes
Tidal volume variation
Time frame: During a 4 hour cross-over period on either intervention
Oxygen saturation index
Time frame: During a 4 hour cross-over period on either intervention
End-expiratory lung impedance (EELI), End-inspiratory lung impedance (EILI)
Time frame: During a 4 hour cross-over period on either intervention
Transcutaneous carbon dioxide (TcCO2) values in response to varying PEEP levels
Time frame: During a 4 hour cross-over period on either intervention
Respiratory Severity Score (RSS)
Time frame: During a 4 hour cross-over period on either intervention
oxygen saturation (SpO2) values
Time frame: During a 4 hour cross-over period on either intervention
% tidal distribution
Time frame: During a 4 hour cross-over period on either intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Bronchopulmonary Dysplasia
Recruiting
Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)
Premature Infants, Bronchopulmonary Dysplasia
Recruiting
Controlled Remote Monitoring and Optimization of Oxygen Therapy in Preterm Infants
BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension
Not yet recruitingPhase 1/2
Little Lungs Study
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Not yet recruiting
Strap To Reduce Apnea in Preterm Infants: A Randomized Crossover Trial
Apnea of Prematurity, Intermittent Hypoxemia
RecruitingPhase 4
Impact of Higher Zinc Supplementation on Neonatal Weight Velocity
Extreme Prematurity,Extremely Low Birthweight, BPD - Bronchopulmonary Dysplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Colm P Travers, MD contact
Kulsajan S Bhatia, MD principal investigator
University of Alabama at Birmingham
Colm P Travers, MD principal investigator
University of Alabama at Birmingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Increase in the PEEP followed by decrease in the PEEP and Decrease in the PEEP followed by increase in the PEEP in people with Bronchopulmonary Dysplasia and Pulmonary Hypertension Due to Lung Diseases and Hypoxia, run by University of Alabama at Birmingham at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kulsajan S Bhatia, MD (9172149882, ksbhatia@uabmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT (time frame: During a 4 hour cross-over period on either intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.